[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Cook JL, Miura TA, Iklé DN, Lewis AM Jr, Routes JM: E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res; 2003 Jun 15;63(12):3435-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
  • Expression of the adenoviral E1A oncogene induces susceptibility of neoplastic cells from different species to both immune-mediated and chemotherapy-induced cell death.
  • These results were confirmed in studies of E1A-expressing human fibrosarcoma cells.
  • This experimental approach should be useful for studies of the effects of other oncogene-related tumor cell traits on tumorigenicity and could be used for preclinical studies of different treatment strategies for human tumors.
  • [MeSH-major] Adenovirus E1A Proteins / physiology. Apoptosis / physiology. Bone Neoplasms / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Drug Resistance, Neoplasm / physiology. Osteosarcoma / pathology
  • [MeSH-minor] Adenoviruses, Human / genetics. Adenoviruses, Human / physiology. Animals. Antineoplastic Agents / therapeutic use. Cell Line / transplantation. Cytotoxicity, Immunologic. Etoposide / therapeutic use. Female. Fibrosarcoma / immunology. Fibrosarcoma / pathology. Genes, p53. Humans. Immunologic Surveillance. Kidney. Killer Cells, Natural / immunology. Mice. Mice, Nude. Oncogenes. Rats. Rats, Nude. Time Factors. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / immunology. Tumor Suppressor Protein p53 / deficiency. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810682.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA76491; United States / NCI NIH HHS / CA / CA86727
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


2. Takeda K, Uehara M, Tei N, Shimizu K, Imazu T, Yoshimura K, Kiyohara H: [A case of retroperitoneal myxofibrosarcoma]. Hinyokika Kiyo; 2009 Nov;55(11):711-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year-old man presented to our hospital suffering from dull pain in his right flank and general malaise.Abdominal computed tomography (CT) revealed a 21X14 cm retroperitoneal tumor adjacent to the right kidney.
  • Histopathological diagnosis was high-grade myxofibrosarcoma.
  • Because he refused to receive adjuvant chemotherapy,he was observed for 2 months until CT revealed multiple liver metastases and para-aortic lymph node metastasis.
  • He underwent 1 cycle of combined chemotherapy with doxorubicin and carboplatin,but metastatic lesions grew larger rapidly and his general state became too poor to continue chemotherapy.
  • [MeSH-major] Fibrosarcoma / pathology. Retroperitoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946191.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


3. Simonova M, Wall A, Weissleder R, Bogdanov A Jr: Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res; 2000 Dec 1;60(23):6656-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tyrosinase has been suggested as a prodrug-converting enzyme for the treatment of melanoma.
  • We hypothesized that tyrosinase expression in transfected nonmelanotic cells can be used in a gene therapy paradigm of prodrug activation.
  • Expression of mutant and wild-type tyrosinases was induced by transfection in nontumorigenic human cells of epithelial origin (293HEK, MCF-10A adenoma, and NHDF-Ad human dermal fibroblasts) as well as in tumor cells (9L gliosarcoma, MCF7 adenocarcinoma, and HT-1080 fibrosarcoma).
  • When compared with the wild-type tyrosinase transfectants, truncated mutant expression resulted in higher mRNA levels that paralleled higher enzyme activity of the truncated mutants.
  • Effects of prodrug treatment were compared for tumorigenic cells and their nontumorigenic counterparts.
  • Overall, these results indicate that the developed tyrosinase mutants hold promise as prodrug activation systems for tumoral gene therapy.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / pharmacology. Biotransformation. Cell Division / drug effects. Cell Line. Fibrosarcoma / drug therapy. Fibrosarcoma / enzymology. Fibrosarcoma / genetics. Gliosarcoma / drug therapy. Gliosarcoma / enzymology. Gliosarcoma / genetics. Humans. Kidney / cytology. Kidney / enzymology. Melanins / biosynthesis. Mutation. Phenols / pharmacokinetics. Phenols / pharmacology. Propanols / pharmacokinetics. Propanols / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYSTEAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11118049.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5RO1 CA74421-01; United States / NINDS NIH HHS / NS / 5RO1 NS35258-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4-hydroxyphenyl)propanol; 0 / Antineoplastic Agents; 0 / Melanins; 0 / Phenols; 0 / Prodrugs; 0 / Propanols; 0 / RNA, Messenger; 5UX2SD1KE2 / Cysteamine; 91281-32-2 / N-acetyl-4-S-cysteaminylphenol; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


Advertisement
4. Terenzi F, Hui DJ, Merrick WC, Sen GC: Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem; 2006 Nov 10;281(45):34064-71
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Cells, Cultured / metabolism. Cells, Cultured / virology. Fibrosarcoma / drug therapy. Fibrosarcoma / metabolism. Fibrosarcoma / virology. Humans. Immunoprecipitation. Interferon-beta / pharmacology. Kidney / drug effects. Kidney / metabolism. Kidney / virology. Models, Biological. Plasmids. RNA, Double-Stranded / physiology. RNA, Transfer, Met / metabolism. Recombinant Proteins. Ribonucleases. Ribosomes / metabolism. Sendai virus / physiology. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16973618.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62220; United States / NCI NIH HHS / CA / CA68782
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-3; 0 / ISG-54 protein, human; 0 / Met-tRNA(i)(Met); 0 / Proteins; 0 / RNA, Double-Stranded; 0 / RNA, Transfer, Met; 0 / Recombinant Proteins; 0 / Transcription Factors; 0 / interferon-induced 56K protein, human; 77238-31-4 / Interferon-beta; EC 3.1.- / Ribonucleases
  •  go-up   go-down


5. Haslinger B, Kleemann R, Toet KH, Kooistra T: Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int; 2003 Jun;63(6):2065-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells.
  • Human peritoneal mesothelial cells (HMC) play a critical role in maintaining the intraperitoneal balance between fibrinolysis and coagulation by expressing the fibrinolytic enzyme tissue-type plasminogen activator (t-PA) and its specific inhibitor, plasminogen activator inhibitor-1 (PAI-1) as well as the procoagulant protein, tissue factor.
  • METHODS: Cultured HMC were used to examine the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, on the expression of t-PA, PAI-1 and tissue factor after activation of the cells with tumor necrosis factor-alpha (TNF-alpha).
  • Luciferase reporter gene assays and Western blot analysis in human fibrosarcoma HT1080 cells and HMC were performed to analyze the effect of simvastatin on the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1), which regulate tissue factor gene expression.
  • Similarly, simvastatin down-regulated the expression of tissue factor and also completely opposed the TNF-alpha-induced tissue factor expression.
  • The effects of simvastatin on t-PA, PAI-1 and tissue factor expression were prevented by mevalonate and geranylgeraniol (GG), suggesting the involvement of geranylgeranyl-modified intermediates in simvastatin's mode of action.
  • Also, simvastatin reduced NF-kappa B- and AP-1-dependent reporter gene activity in TNF-alpha-treated HT-1080 fibrosarcoma cells and reduced the nuclear levels of p50-NF-kappa B, p65-NF-kappa B, and the AP-1 components c-fos and c-jun in HMC.
  • Our findings provide a molecular explanation for the anti-inflammatory properties of statins in HMC and a rationale for the use of these drugs to protect peritoneal dialysis patients from peritoneal fibrosis and adhesion development during bacterial peritonitis.
  • [MeSH-major] Fibrinolysis / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Peritoneum / cytology. Simvastatin / pharmacology. Thromboplastin / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cells, Cultured. Diterpenes / pharmacology. Epithelial Cells / cytology. Epithelial Cells / drug effects. Epithelium. Gene Expression / drug effects. Humans. Mevalonic Acid / pharmacology. Omentum / cytology. Peritoneal Dialysis. Peritonitis / drug therapy. Plasminogen Activator Inhibitor 1 / genetics. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. MEVALONIC ACID .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753293.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Plasminogen Activator Inhibitor 1; 0 / Tumor Necrosis Factor-alpha; 9035-58-9 / Thromboplastin; AGG2FN16EV / Simvastatin; AIA02AJA3A / geranylgeraniol; S5UOB36OCZ / Mevalonic Acid
  •  go-up   go-down


6. Russell H, Hicks MJ, Bertuch AA, Chintagumpala M: Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer; 2009 Jul;53(1):23-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy.
  • BACKGROUND: Infantile fibrosarcoma (IF) is a rare soft tissue sarcoma that presents either at birth or in the first year of life.
  • Complete surgical resection is usually curative but chemotherapy may shrink the tumor to facilitate complete resection.
  • This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection.
  • PROCEDURE: A retrospective review was performed of patients treated between 2000 and 2007.
  • Two lower extremity tumors had only modest changes in dimensions but upon resection, the tumor bed contained fibrous tissue with exaggerated small caliber vessels.
  • The fourth infant developed metastatic lesions in the central nervous system, orbits, lungs, and kidney after complete removal of the primary tumor.
  • The metastatic lesions responded to chemotherapy and have remained stable for over 3 years.
  • In patients where a clinical response is not apparent, cytoreduction of the tumor and replacement with fibrotic and fibrovascular tissue may facilitate gross-total resection.
  • The chemotherapy-responsiveness of this tumor may abrogate unfavorable features such as metastatic or residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Infant. Infant, Newborn. Leg. Lymphatic Metastasis. Male. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19340853.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


7. Sotolongo Vergo I, Suárez Cabrera RE, Arencibia García J: [Retroperitoneal fibrosarcoma. Apropos of a case]. Arch Esp Urol; 2003 May;56(4):421-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal fibrosarcoma. Apropos of a case].
  • [Transliterated title] Fibrosarcoma retroperitoneal. A propósito de un caso.
  • OBJECTIVES: To report one case of retroperitoneal fibrosarcoma in a 45 year-old caucasian patient cared for at the Public Health System hospitals in Republic of Cuba.
  • Intravenous urography showed that left kidney was displaced towards midline but presented a good contrast uptake and excretion.
  • Renal ultrasound discovered a large hyperechogenic mass with internal calcifications.
  • CT scan confirmed a left flank tumor with internal necrosis which displaced the kidney.
  • Complete tumour resection was performed confirmatory of the histological diagnosis of retroperitoneal fibrosarcoma.
  • Postoperative chemotherapy was administered.
  • [MeSH-major] Fibrosarcoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Back Pain / etiology. Calcinosis / etiology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Fatal Outcome. Hematuria / etiology. Humans. Lung Neoplasms / complications. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Pulmonary Embolism / etiology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12830615.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Loeb DM, Hill DA, Dome JS: Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol; 2002 Aug-Sep;24(6):478-81
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy.
  • The sensitivity of this tumor to chemotherapy is unknown.
  • The recent description of a t(12;15)(p13;q25) chromosomal translocation in both cellular CMN and congenital infantile fibrosarcoma suggests that these entities have a common pathogenesis, and that cellular CMN might respond to chemotherapy like congenital infantile fibrosarcoma does.
  • The authors describe three patients with recurrent cellular CMN who showed a complete response to chemotherapy.
  • Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nephroma, Mesoblastic / drug therapy


9. Patel Y, Mitchell CD, Hitchcock RJ: Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology; 2003 Jun;61(6):1260
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
  • A more aggressive cellular form, however, that has a close relationship to congenital fibrosarcoma, is widely described.
  • We describe a patient with isolated metastasis to liver and review the management, together with evidence that it may be more appropriate to use a vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) regimen rather than Wilm's tumor-based regimens in those cases for which chemotherapy is indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / congenital. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secretion. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / secondary. Sarcoma / drug therapy


10. Rohini G, Sabitha KE, Devi CS: Bacopa monniera Linn. extract modulates antioxidant and marker enzyme status in fibrosarcoma bearing rats. Indian J Exp Biol; 2004 Aug;42(8):776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacopa monniera Linn. extract modulates antioxidant and marker enzyme status in fibrosarcoma bearing rats.
  • Antioxidative property and tumor inhibitive property of B. monniera (20mg/kg body wt, sc) was examined in 3-methylcholanthrene induced fibrosarcoma rats.
  • Antioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) and the levels of glutathione (GSH) and the rate of lipid peroxidation (LPO) in the liver and kidney tissues were assessed.
  • A significant increase was noted for the rate of LPO with a corresponding decrease in the antioxidant enzyme status in fibrosarcoma bearing rats.
  • In fibrosarcoma bearing rats, the tumor markers like lactate dehydrogenase (LDH), creatine kinase (CK), alanine transaminase (ALT), aspartate transaminase (AST) and sialic acid (SA) were increased in the serum.
  • Treatment with B. monniera extract significantly increased the antioxidant enzyme status, inhibited lipid peroxidation and reduced the tumor markers.
  • It can be concluded that B.monniera extract promotes the antioxidant status, reduces the rate of lipid peroxidation and the markers of tumor progression in the fibrosarcoma bearing rats.
  • [MeSH-major] Bacopa. Fibrosarcoma / drug therapy. Phytotherapy
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Antioxidants / metabolism. Biomarkers, Tumor / metabolism. Lipid Peroxidation / drug effects. Male. Plant Extracts / pharmacology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15573526.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Plant Extracts
  •  go-up   go-down


11. McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol; 2003 May;40(5):288-92
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy.
  • BACKGROUND: Recently, the ETV6-NTRK3 gene fusion has been identified in both infantile fibrosarcoma and cellular mesoblastic nephroma.
  • For both these tumors standard curative treatment has been primarily surgical with wide local excision.
  • PROCEDURE: This report discusses three infants with congenital tumors, two congenital fibrosarcomas, and one atypical congenital mesoblastic nephroma, not easily amenable to surgical intervention.
  • RESULTS: All three were treated with pre-operative chemotherapy with excellent responses negating the need for amputation in two patients.
  • In this group of patients pre-operative chemotherapy may abrogate the need for morbid surgical procedures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / genetics. Fibrosarcoma / congenital. Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital. Receptor, trkC / genetics. Repressor Proteins / genetics. Soft Tissue Neoplasms / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12652616.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Genetic Markers; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


12. Xiang J, Tang J, Song C, Yang Z, Hirst DG, Zheng QJ, Li G: Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy; 2009;11(5):516-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma.
  • BACKGROUND AIMS: Cell-based gene therapy is an alternative to viral and non-viral gene therapy.
  • Emerging evidence suggests that mesenchymal stem cells (MSC) are able to migrate to sites of tissue injury and have immunosuppressive properties that may be useful in targeted gene therapy for sustained specific tissue engraftment.
  • ) 1x10(6) MSC, isolated from green fluorescent protein (GFP) transgenic rats, into Rif-1 fibrosarcoma-bearing C3H/HeN mice.
  • RESULTS: We observed that xenogenic MSC selectively migrated to the tumor site, proliferated and expressed the exogenous gene in subcutaneous fibrosarcoma transplants.
  • No MSC distribution was detected in other organs, such as the liver, spleen, colon and kidney.
  • We further showed that the FGF2/FGFR pathways may play a role in the directional movement of MSC to the Rif-1 fibrosarcoma.
  • We performed in vitro co-culture and in vivo tumor growth analysis, showing that MSC did not affect the proliferation of Rif-1 cells and fibrosarcoma growth compared with an untreated control group.
  • Finally, we demonstrated that the xenogenic MSC stably expressing inducible nitric oxide synthase (iNOS) protein transferred by a lentivirus-based system had a significant inhibitory effect on the growth of Rif-1 tumors compared with MSC alone and the non-treatment control group.
  • MSC may be used as a target gene delivery vehicle for the treatment of fibrosarcoma and other tumors.
  • [MeSH-major] Fibrosarcoma / genetics. Fibrosarcoma / therapy. Genetic Therapy. Mesenchymal Stromal Cells / cytology
  • [MeSH-minor] Animals. Cell Line. Cell Movement / drug effects. Cell Proliferation / drug effects. Fibroblast Growth Factor 2 / pharmacology. Green Fluorescent Proteins / metabolism. Humans. Mesenchymal Stem Cell Transplantation. Mice. Neoplasm Transplantation. Nitric Oxide Synthase Type II / metabolism. Rats. Subcutaneous Tissue / drug effects. Subcutaneous Tissue / pathology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562576.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2; 147336-22-9 / Green Fluorescent Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


13. Kondo Y, Himeno S, Satoh M, Naganuma A, Nishimura T, Imura N: Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum. Cancer Chemother Pharmacol; 2004 Jan;53(1):33-8
Hazardous Substances Data Bank. CITRIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent.
  • We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mice.
  • Bismuth subnitrate (BSN) is used as an antigastric ulcer agent and as an antidiarrheic agent, and is suitable for inducing MT in the kidney in cancer patients.
  • However, due to the low absorption rate of Bi from the gastrointestinal tract, the efficacy of BSN in inducing renal MT is low.
  • In the present study, we examined the effects of citrate as a vehicle for oral administration of BSN on the tissue distribution of Bi and induction of MT in the kidneys and tumors in mice inoculated with Meth-A fibrosarcoma.
  • Renal levels of MT and Bi were markedly increased in the mice given BSN dissolved in citrate solution compared with those given BSN suspended in saline.
  • Administration of BSN with citrate efficiently depressed the renal toxicity of CDDP, but did not affect its antitumor activity.
  • [MeSH-major] Bismuth / therapeutic use. Cisplatin / toxicity. Citric Acid / pharmacology. Fibrosarcoma / drug therapy. Kidney / drug effects. Protective Agents / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Drug Synergism. Kidney Diseases / prevention & control. Male. Metallothionein / biosynthesis. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Tissue Distribution

  • Hazardous Substances Data Bank. BISMUTH SUBNITRATE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14530870.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protective Agents; 2968PHW8QP / Citric Acid; 9038-94-2 / Metallothionein; H19J064BA5 / bismuth subnitrate; Q20Q21Q62J / Cisplatin; U015TT5I8H / Bismuth
  •  go-up   go-down


14. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C: Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging; 2004 Jan;31(1):117-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor hypoxia, present in many human cancers, can lead to resistance to radiation and chemotherapy, is associated with a more aggressive tumor phenotype and is an independent prognostic factor of clinical outcome.
  • In the current study, serial microPET imaging was used to evaluate iodine-124-labeled iodo-azomycin-galactoside ((124)I-IAZG) (4.2-day physical half-life) as a hypoxia imaging agent in 17 MCa breast tumors and six FSaII fibrosarcomas implanted in mice.
  • Region-of-interest analysis was performed as a function of time p.i. and indicated a tumor uptake of 5-10% (of total-body activity) for FMISO at 3-6 h p.i., and of ~17% for IAZG at 48 h p.i.
  • This was corroborated by biodistribution data in that the tumor-to-normal tissue (T/N, normal tissues of blood, heart, lung, liver, spleen, kidney, intestine, and muscle) activity ratios of IAZG at 24 h p.i. was 1.5-2 times higher than those of FMISO at 3 h p.i., with the exception of stomach.
  • [MeSH-major] Cell Hypoxia. Fibrosarcoma / diagnostic imaging. Fibrosarcoma / metabolism. Mammary Neoplasms, Animal / diagnostic imaging. Mammary Neoplasms, Animal / metabolism. Misonidazole / analogs & derivatives. Monosaccharides / pharmacokinetics. Nitroimidazoles / pharmacokinetics. Tomography, Emission-Computed / methods
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Metabolic Clearance Rate. Mice. Mice, Inbred C3H. Organ Specificity. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):229-37 [9572615.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):417-28 [8892467.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):467-72 [11586098.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50 [12692685.001]
  • [Cites] Radiat Res. 1988 Apr;114(1):64-76 [2895486.001]
  • [Cites] Med Phys. 1991 May-Jun;18(3):357-66 [1870476.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):337-44 [11216534.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1643-52 [11696633.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):177-83 [9935074.001]
  • [Cites] Appl Radiat Isot. 2001 Jan;54(1):73-80 [11144255.001]
  • [Cites] J Nucl Med. 2000 Feb;41(2):327-36 [10688119.001]
  • [Cites] Brain Res. 1995 Jul 10;685(1-2):91-8 [7583257.001]
  • [Cites] Semin Nucl Med. 2001 Oct;31(4):321-9 [11710774.001]
  • [Cites] Br J Cancer. 1955 Dec;9(4):539-49 [13304213.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1557-62 [8790218.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8 [12654432.001]
  • [Cites] Radiat Res. 2001 Jun;155(6):837-46 [11352767.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S209-12 [8763882.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):167-73 [12105986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82 [11240261.001]
  • [Cites] Pharm Res. 1994 Mar;11(3):466-9 [8008718.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17 (5):985-91 [2808061.001]
  • (PMID = 14523586.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA84596; United States / NCI NIH HHS / CA / R24 CA83084
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Monosaccharides; 0 / Nitroimidazoles; 0 / iodinated azomycin galactopyranoside; 082285VIDF / fluoromisonidazole; 8FE7LTN8XE / Misonidazole
  •  go-up   go-down


15. Murugesan S, Shetty SJ, Srivastava TS, Samuel AM, Noronha OP: Preparation and biological evaluation of the new chlorin photosensitizer T3,4BCPC for detection and treatment of tumors. J Photochem Photobiol B; 2002 Aug;68(1):33-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation and biological evaluation of the new chlorin photosensitizer T3,4BCPC for detection and treatment of tumors.
  • The radiotracer was evaluated for tissue distribution in Wistar rats.
  • Accumulation of administrated activities in the liver, kidney, bladder and large intestine at 4 h post-injection indicated that the labeled ligand was largely eliminated through the renal and partly through the hepatobiliary system.
  • However, in the transplanted rat C(6)-glioma, the T/M ratio of the labeled compound was appreciably higher (four-fold) than that noted with 99mTc(V)-DMSA (two-fold), 201TlCl (three-fold) and 99mTc-citrate (more than three-fold).
  • These findings suggest that the radiolabeled T3,4BCPC may have potential for the detection of cancer.
  • In order to ascertain the efficacy of the compound for photodynamic therapy applications, a preclinical PDT study was carried out in fibrosarcoma-bearing mice after injecting 5.0 mg/kg body weight of the T3,4BCPC.
  • The labeled agent could also be useful in monitoring the progression/regression of tumors before, during, and after chemotherapy, radiation therapy or PDT.
  • [MeSH-major] Anthracenes / pharmacokinetics. Anthracenes / therapeutic use. Glioma / drug therapy. Mammary Neoplasms, Experimental / drug therapy. Neoplasms / drug therapy. Photosensitizing Agents / pharmacokinetics. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Technetium
  • [MeSH-minor] Animals. Female. Isotope Labeling / methods. Male. Methylnitrosourea. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / therapeutic use. Rats. Rats, Wistar. Time Factors. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science B.V.
  • (PMID = 12208034.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 5,10,15,20-tetrakis(3,4-bis(carboxymethyleneoxy)phenyl)chlorin; 0 / Anthracenes; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Radiopharmaceuticals; 684-93-5 / Methylnitrosourea; 7440-26-8 / Technetium
  •  go-up   go-down


16. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • CONCLUSIONS: Diagnosis of congenital tumors is performed earlier in recent years due to the wide use of prenatal ultrasound.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • We ought to pass this message on to our colleagues in prenatal diagnosis, so parents get reliable information.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Llop E, Gutiérrez-Gallego R, Segura J, Mallorquí J, Pascual JA: Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Anal Biochem; 2008 Dec 15;383(2):243-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a novel recombinant human erythropoietin (epoetin delta, Dynepo) has been marketed in the European Union for the treatment of chronic kidney disease, cancer patients receiving chemotherapy, and so forth.
  • Epoetin delta is engineered in cultures of the human fibrosarcoma cell line HT-1080 by homologous recombination and "gene activation."
  • Unlike recombinant erythropoietins produced in other mammalian cells, epoetin delta is supposed to have a human-type glycosylation profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804089.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Polysaccharides; 0 / Protein Isoforms; 0 / Recombinant Proteins; 0 / epoetin delta; 11096-26-7 / Erythropoietin; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


18. Jelkmann W: Control of erythropoietin gene expression and its use in medicine. Methods Enzymol; 2007;435:179-97
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EPO deficiency is the main cause of the anemia in chronic kidney disease (CKD) and a contributing factor in the anemias of inflammation and cancer.
  • Small, orally active compounds capable of stimulating endogenous EPO production are in preclinical or clinical trials for treatment of anemia.
  • While HIF stabilizing drugs may prove useful as inexpensive second-line choices, at present, their side effects--particularly tumorigenicity--preclude their use as first-choice therapy.
  • As an alternative, EPO gene therapy has been explored in animal studies and in trials on CKD patients.
  • Recombinant human EPO (rhEPO) engineered in Chinese hamster ovary (CHO) cell cultures (epoetin alpha and epoetin beta [beta]) and its hyperglycosylated analogue darbepoetin alpha are established and safe drugs to avoid allogeneic red blood cell transfusion.
  • Gene-activated EPO (epoetin delta [delta]) from human fibrosarcoma cells (HT-1080) has recently been launched for use in CKD.
  • It is important to know the basics of the technologies, production processes, and structural properties of the novel anti-anemic strategies and drugs.
  • [MeSH-major] Erythropoietin / genetics. Erythropoietin / metabolism. Erythropoietin / therapeutic use. Gene Expression Regulation. Genetic Therapy
  • [MeSH-minor] Gene Expression / drug effects. Gene Transfer Techniques. Genetic Engineering. Humans. Recombinant Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998055.001).
  • [ISSN] 0076-6879
  • [Journal-full-title] Methods in enzymology
  • [ISO-abbreviation] Meth. Enzymol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  • [Number-of-references] 109
  •  go-up   go-down


19. Weber W, Fux C, Daoud-el Baba M, Keller B, Weber CC, Kramer BP, Heinzen C, Aubel D, Bailey JE, Fussenegger M: Macrolide-based transgene control in mammalian cells and mice. Nat Biotechnol; 2002 Sep;20(9):901-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterologous mammalian gene regulation systems for adjustable expression of multiple transgenes are necessary for advanced human gene therapy and tissue engineering, and for sophisticated in vivo gene-function analyses, drug discovery, and biopharmaceutical manufacturing.
  • The macrolide-responsive E.REX technology was functionally compatible with the streptogramin (PIP-regulated and tetracycline (TET-regulated expression systems, and therefore may be combined for multiregulated multigene therapeutic interventions in mammalian cells and tissues.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. Erythromycin / pharmacology. Gene Expression Regulation / drug effects. Transgenes / drug effects. Transgenes / genetics
  • [MeSH-minor] Alkaline Phosphatase / genetics. Alkaline Phosphatase / secretion. Animals. Base Sequence. CHO Cells / drug effects. CHO Cells / metabolism. Cell Line. Cricetinae. Dose-Response Relationship, Drug. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Escherichia coli / genetics. Escherichia coli / metabolism. Female. Fibroblasts / drug effects. Fibroblasts / metabolism. Fibrosarcoma / metabolism. Humans. Kidney / embryology. Mice. Molecular Sequence Data. Trans-Activators / genetics. Transduction, Genetic. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12205509.001).
  • [ISSN] 1087-0156
  • [Journal-full-title] Nature biotechnology
  • [ISO-abbreviation] Nat. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Trans-Activators; 63937KV33D / Erythromycin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


20. Arsenyan P, Shestakova I, Rubina K, Domracheva I, Nesterova A, Vosele K, Pudova O, Lukevics E: Organoammonium hydroselenites: antitumor action through radical balance regulation. Eur J Pharmacol; 2003 Apr 4;465(3):229-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These compounds were studied in vitro on human fibrosarcoma (HT-1080), hamster kidney endothelial (BHK 21) and normal mouse embryonic fibroblasts (NIH 3T3).
  • The substances studied were also active in vivo against sarcoma S-180.
  • The role of organoammonium hydroselenites as free radical regulators and their therapeutic antitumor are discussed.
  • [MeSH-minor] Animals. Catalase / antagonists & inhibitors. Catalase / metabolism. Cell Line, Tumor. Cricetinae. Drug Screening Assays, Antitumor. Endothelium / drug effects. Endothelium / physiology. Free Radicals / metabolism. Glutathione Peroxidase / antagonists & inhibitors. Glutathione Peroxidase / metabolism. Mice. Sarcoma 180 / drug therapy. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12681434.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Free Radicals; 0 / Organoselenium Compounds; 0 / Quaternary Ammonium Compounds; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


21. Lowichik A, Zhou H, Pysher TJ, Smith L, Lemons R, Coffin CM: Therapy associated changes in childhood tumors. Adv Anat Pathol; 2000 Nov;7(6):341-59
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy associated changes in childhood tumors.
  • Contemporary treatment regimens for the common solid tumors of childhood have led to increased numbers of post-treatment pathologic specimens from survivors.
  • Current therapeutic strategies for childhood cancers in North America require an accurate pathologic diagnosis and stratify patients based on combinations of clinical, biological, and pathologic features.
  • In several tumor systems, the pathologic response to therapy also modifies the treatment regimen.
  • Accurate pathologic interpretation of such specimens is critical in providing useful prognostic information for therapeutic decisions.
  • Standardized handling of post-therapy pathologic specimens, appropriate use of molecular and genetic studies, consideration of the differential diagnoses, and assessment of the potential biologic significance of therapy-induced pathologic changes are, therefore, critical for patient management and determination of treatment protocols.
  • [MeSH-minor] Adolescent. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Child. Child, Preschool. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Hepatoblastoma / pathology. Hepatoblastoma / therapy. Histocytochemistry. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Liver Neoplasms / pathology. Liver Neoplasms / therapy. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Osteosarcoma / pathology. Osteosarcoma / surgery. Prognosis. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Wilms Tumor / drug therapy. Wilms Tumor / pathology. Wilms Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078058.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 149
  •  go-up   go-down


22. Mirshafiey A, Rehm B, Sotoude M, Razavi A, Abhari RS, Borzooy Z: Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol; 2007;29(1):49-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis.
  • The therapeutic efficacy of novel designed nonsteroidal anti-inflammatory drug, M2000 (beta- D- mannuronic acid) on experimental immune complex glomerulonephritis was evaluated.
  • Onset of treatment was day 56.
  • Animals were killed on day 84 and blood samples and kidney specimens were obtained.
  • Serum (creatinine, blood urea nitrogen, cholesterol, and triglyceride) and urine (protein, urea, and creatinine) determinants were measured at the time of sacrifice.
  • Kidney specimens were processed for light and immunofluorescent microscopic examination.
  • The fibrosarcoma cell line was used for assaying tolerability and matrix metalloproteinase type 2 (MMP-2) activity.
  • Our data showed that M2000 therapy could significantly reduce the urinary protein excretion in treated rats versus non-treated controls.
  • Cytotoxicity analysis of M2000 showed a much higher tolerability compared with other tested drugs (diclofenac, piroxicam and dexamethasone).
  • Moreover, the toxicological study revealed that M2000 had no influence on serum (BUN, creatinine, triglyceride and cholesterol) determinants, urinary protein excretion and glomerular histology in healthy group receiving drug.
  • CONCLUSIONS: These findings suggest that treatment with M2000 can reduce proteinuria, diminish antibody production, and suppress the progression of disease in a rat model of immune complex glomerulonephritis.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Glomerulonephritis / drug therapy. Hexuronic Acids / pharmacology
  • [MeSH-minor] Animals. Antigen-Antibody Complex / metabolism. Drug Design. Drug Evaluation, Preclinical. Female. Matrix Metalloproteinase 2 / metabolism. Proteinuria / blood. Proteinuria / chemically induced. Proteinuria / drug therapy. Proteinuria / pathology. Proteinuria / urine. Rats. Rats, Sprague-Dawley. Serum Albumin, Bovine / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464766.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antigen-Antibody Complex; 0 / Hexuronic Acids; 0 / Serum Albumin, Bovine; 980IT47Y34 / mannuronic acid; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


23. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D'Incalci M, Riccardi R: Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol; 2003 Aug;52(2):131-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
  • PURPOSE: To investigate the cytotoxic and antitumor effects of the combination of the novel anticancer drug ET-743 and doxorubicin (Dx) and to determine whether any pharmacokinetic interaction occurs in sarcoma-bearing mice.
  • METHODS: The cytotoxicity of each drug and of their combinations was assessed in the rhabdomyosarcoma cell line TE-671 by a clonogenic assay, and isobologram analysis was performed to detect any synergistic, additive or antagonistic effects.
  • The antitumor activities of each drug and of the combinations were also evaluated in nude mice transplanted subcutaneously with human TE-671 rhabdomyosarcoma and in C3H female mice injected intravenously with UV2237 M fibrosarcoma or with the Dx-resistant subline UV2237 M-ADM which overexpresses Pgp.
  • Antitumor activity was evaluated by monitoring the TE-671 tumor volume over time and, in the case of the murine fibrosarcomas, by evaluation of lung deposits at autopsy quantified by determining lung weight.
  • ET-743 was determined in plasma by an HPLC-MS method and Dx in plasma and tissue by an HPLC method with fluorescence detection.
  • Giving ET-743 1 h before Dx slightly enhanced the effect (LCK 1.12) compared with giving the drugs simultaneously (LCK 0.85) or in the opposite sequence (LCK 0.92).
  • In UV2237 M fibrosarcoma, both Dx and ET-743 showed an effect in reducing the weight of lung metastases, although the combination of the two drugs was not superior to each drug alone.
  • In UV2237 M-ADM tumors neither of the two drugs was active, whereas the combination, particularly when the two drugs were given simultaneously, produced a significant effect.
  • Plasma levels of ET-743 and Dx were not significantly different when the drugs were given alone or in combination.
  • The concentrations of Dx in tissues including tumor, liver, heart and kidney were found to be the same whether the drug was given alone or in combination with ET-743.
  • CONCLUSIONS: These results indicate that ET-743 and Dx in combination produce an additive effect against human sarcoma cells, reinforcing the idea that they act by a different mechanism of action.
  • In mice no pharmacokinetic interaction between the two drugs was found.
  • The observed activity in UV2237 M-ADM and in human TE-671 sarcoma suggests that the combination of the two drugs could be effective for tumors displaying low sensitivity to each drug given alone.
  • Based on these findings a phase I study on the combination of the two drugs was recently initiated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cell Survival / drug effects. Dioxoles / administration & dosage. Dioxoles / pharmacology. Doxorubicin / administration & dosage. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Drug Synergism. Female. Humans. Inhibitory Concentration 50. Isoquinolines / administration & dosage. Isoquinolines / pharmacology. Mice. Mice, Inbred C3H. Mice, Nude. Neoplasm Transplantation. Tetrahydroisoquinolines. Tissue Distribution. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12783202.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 80168379AG / Doxorubicin
  •  go-up   go-down


24. Mirshafiey A, Rehm B, Abhari RS, Borzooy Z, Sotoude M, Razavi A: Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol; 2007 Jul;24(1):60-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental nephritis.
  • The present research introduces the method of Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental model of nephritis.
  • M2000 was produced using enzymatic and chemical procedure on prepared alginate from Pseudomonas fluorescens.
  • Onset of treatment was day 56.
  • Animals were killed on day 84 and blood samples and kidney specimens were obtained.
  • Serum (creatinine, BUN, cholesterol, and triglyceride) and urine (protein, urea, and creatinine) determinants were measured at the time of sacrifice.
  • Kidney specimens were processed for light and immunofluorescent microscopic examination.
  • The fibrosarcoma cell line was used for assaying tolerability and matrix metalloproteinase type 2 (MMP-2) activity.
  • Our data showed that M2000 therapy could significantly reduce the urinary protein excretion in treated rats versus non-treated controls.
  • Cytotoxicity analysis of M2000 showed a much higher tolerability compared with other tested drugs (diclofenac, piroxicam and dexamethasone).
  • Moreover, the toxicological study revealed that M2000 had no influence on serum (BUN, creatinine, triglyceride and cholesterol) determinants, urinary protein excretion and glomerular histology in healthy group receiving drug.
  • CONCLUSIONS: In this research, for the first time we introduced the procedure of production of M2000 (β-d-mannuronic acid) and our data suggest that treatment with M2000, as a novel anti-inflammatory drug can reduce proteinuria, diminish antibody production and suppress the progression of disease in experimental model of glomerulonephritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007. Published by Elsevier B.V.
  • (PMID = 21783790.001).
  • [ISSN] 1382-6689
  • [Journal-full-title] Environmental toxicology and pharmacology
  • [ISO-abbreviation] Environ. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Mirshafiey A, Cuzzocrea S, Rehm BH, Matsuo H: M2000: a revolution in pharmacology. Med Sci Monit; 2005 Aug;11(8):PI53-63
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The tolerability and the anti-inflammatory and immunosuppressive properties of a novel designed non-steroidal anti-inflammatory drug, M2000 (beta-D-mannuronic acid), were investigated in various experimental models.
  • Its therapeutic potency on kidney diseases was studied using experimental models of nephrosis and immune complex glomerulonephritis (ICG).
  • Biocompatibility and pharmacotoxicology assessment of M2000 was carried out using a fibrosarcoma cell line, zymography, and serum and urine determinants.
  • Lymph node cell proliferation assay in EAE confirmed the immunosuppressive efficacy of the tested drug.
  • Moreover, this drug inhibited MMP-2 activity.
  • The pharmacotoxicology study showed that M2000 is the safest anti-inflammatory and immunosuppressive drug in comparison with dexamethasone and conventional NSAIDs tested.
  • CONCLUSIONS: M2000 is the first novel designed NSAID with the lowest molecular weight, no gastro-nephrotoxicity, and therapeutic effects in glomerulonephritis and nephrosis and could be strongly recommended on an extensive scale as the safest drug for decreasing anti-inflammatory reactions.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Glomerulonephritis / drug therapy. Hydrocarbons / pharmacology. Hydrocarbons / therapeutic use. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Animals. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies / immunology. Arthritis, Experimental / drug therapy. Arthritis, Experimental / pathology. Cattle. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Hindlimb / drug effects. Hindlimb / pathology. Immunosuppression. Interleukin-6 / biosynthesis. Interleukin-6 / metabolism. Lipids / blood. Male. Matrix Metalloproteinase 2 / metabolism. Mice. Neurons / drug effects. Neurons / pathology. Rats. Rats, Inbred Lew. Serum Albumin, Bovine / immunology

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049391.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies; 0 / Hydrocarbons; 0 / Interleukin-6; 0 / Lipids; 0 / Serum Albumin, Bovine; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


26. Ohmura Y, Matsunaga K, Motokawa I, Sakurai K, Ando T: Protective effects of a protein-bound polysaccharide, PSK, against Candida albicans infection in syngeneic tumor-bearing mice via Th1 cell functions. Cancer Biother Radiopharm; 2003 Oct;18(5):769-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In BALB/c mice that had received subcutaneous (sc) transplantation of fibrosarcoma Meth A, viable fungal counts were increased in the kidney and the mean survival period was shortened after challenge with C. albicans, compared with healthy mice.
  • Treatments with anti-IL-12 or anti-IFN-gamma antibody reduced the anti-infectious effects of PSK.
  • [MeSH-major] Candida albicans / immunology. Candidiasis / drug therapy. Candidiasis / immunology. Neoplasms / drug therapy. Proteoglycans / metabolism. Proteoglycans / therapeutic use. Th1 Cells / immunology
  • [MeSH-minor] Animals. Antibodies / immunology. Antibodies / pharmacology. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. Female. Interferon-gamma / antagonists & inhibitors. Interferon-gamma / genetics. Interferon-gamma / immunology. Interferon-gamma / metabolism. Interleukin-12 / antagonists & inhibitors. Interleukin-12 / genetics. Interleukin-12 / immunology. Interleukin-4 / metabolism. Mice. Mice, Inbred BALB C. Neoplasm Transplantation / immunology. Spleen / drug effects. Spleen / immunology. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14629825.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Proteoglycans; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 66455-27-4 / krestin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement